{"id":"placebo-for-nortriptyline","safety":{"commonSideEffects":[{"rate":null,"effect":"Placebo response (symptom improvement without active drug)"}]},"_chembl":{"chemblId":"CHEMBL1201156","moleculeType":"Small molecule","molecularWeight":"299.85"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is a non-active substance administered in controlled trials to establish a baseline for comparison against the active drug being tested. Any therapeutic benefit observed in placebo recipients is attributed to natural disease progression, regression to the mean, or psychological/expectancy effects. This allows researchers to isolate the true pharmacological efficacy of the investigational drug (nortriptyline in this case) by subtracting placebo response rates from active treatment response rates.","oneSentence":"Placebo produces no pharmacological effect and serves as an inert control in clinical trials to measure the baseline therapeutic response independent of drug action.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:21.239Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in nortriptyline phase 3 clinical trial"}]},"trialDetails":[{"nctId":"NCT07498140","phase":"NA","title":"Procedural Framing and Epidural Steroid Injection Outcomes","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2026-03-25","conditions":"Lumbosacral Radiculopathy","enrollment":210},{"nctId":"NCT03844412","phase":"PHASE2","title":"Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-11-04","conditions":"Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome","enrollment":209},{"nctId":"NCT04226365","phase":"PHASE4","title":"Pediatric Concussion Outcomes","status":"TERMINATED","sponsor":"Lancaster General Hospital","startDate":"2020-02-15","conditions":"Concussion Post Syndrome, Headaches Posttraumatic, Mild Traumatic Brain Injury","enrollment":8},{"nctId":"NCT03652571","phase":"PHASE3","title":"Nortriptyline for the Treatment of Functional Dyspepsia","status":"TERMINATED","sponsor":"Maastricht University Medical Center","startDate":"2018-09-01","conditions":"Functional Dyspepsia","enrollment":96},{"nctId":"NCT05582837","phase":"PHASE4","title":"Treatment of Meniere's Disease With Migraine Medications","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2022-08-01","conditions":"Ménière","enrollment":100},{"nctId":"NCT03652870","phase":"PHASE3","title":"Antidepressants Trial in Parkinson's Disease","status":"COMPLETED","sponsor":"University College, London","startDate":"2021-03-05","conditions":"Depression, Parkinson Disease","enrollment":52},{"nctId":"NCT04404439","phase":"PHASE4","title":"Treatment of Tinnitus With Migraine Medications","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2019-09-26","conditions":"Tinnitus, Subjective, Tinnitus","enrollment":150},{"nctId":"NCT00765895","phase":"PHASE3","title":"Nortriptyline for Idiopathic Gastroparesis","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2009-01","conditions":"Idiopathic Gastroparesis","enrollment":130},{"nctId":"NCT00547703","phase":"NA","title":"Effect of Nortriptyline on Abdominal Pain/Discomfort and Quality of Life in Patients With Nonulcer Dyspepsia","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2008-02","conditions":"Non Ulcer Dyspepsia","enrollment":5},{"nctId":"NCT00539240","phase":"PHASE2, PHASE3","title":"Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2006-04","conditions":"Gastroesophageal Reflux Disease","enrollment":236},{"nctId":"NCT00045916","phase":"PHASE4","title":"Optimizing Electroconvulsive Therapy for Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2001-02","conditions":"Depression, Depressive Disorder, Bipolar Disorder","enrollment":340},{"nctId":"NCT01065649","phase":"PHASE3","title":"Effect of Nortriptyline in Cortical Representation of Heartburn in Nonerosive Reflux Disease (NERD) Patients","status":"COMPLETED","sponsor":"Universidade de Passo Fundo","startDate":"2010-01","conditions":"Gastroesophageal Reflux Disease","enrollment":20},{"nctId":"NCT00018148","phase":"PHASE2","title":"Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"1998-04","conditions":"Smoking","enrollment":158}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (for nortriptyline)","genericName":"Placebo (for nortriptyline)","companyName":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","companyId":"national-institute-of-diabetes-and-digestive-and-kidney-diseases-niddk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo produces no pharmacological effect and serves as an inert control in clinical trials to measure the baseline therapeutic response independent of drug action. Used for Control arm in nortriptyline phase 3 clinical trial.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}